{"schema_version":"secwatch.filing_event.v1","accession":"0001819790-25-000007","form_type":"8-K","ticker":"TARS","cik":"0001819790","company_name":"Tarsus Pharmaceuticals, Inc.","filed_at":"2025-02-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.055053+00:00","generated_at":"2026-05-26T04:54:55.883279+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Tarsus Q4 XDEMVY sales $66.4M; full-year $180.1M; net loss narrows to $0.60/share","bullets":["Q4 net product sales $66.4M (vs $13.1M YoY); full-year $180.1M (vs $14.7M), with 163,000 bottles dispensed in 2024.","Net loss $23.1M ($0.60/share) in Q4 vs $41.9M ($1.31) in Q4 2023; full-year loss $115.6M ($3.07) vs $135.9M ($4.62).","Cash and marketable securities $291.4M as of Dec 31, 2024; gross-to-net discount ~45% on XDEMVY.","Pipeline: TP-04 for ocular rosacea on track to start Phase 2 in H2 2025; TP-05 for Lyme disease Phase 2 study planned.","Appointed Dr. Elizabeth Yeu as CMO and Dr. Katherine Goodrich to Board of Directors."],"urls":{"canonical":"https://secwatch.observer/filing/0001819790-25-000007","json":"https://secwatch.observer/filing/0001819790-25-000007.json","markdown":"https://secwatch.observer/filing/0001819790-25-000007.md","text":"https://secwatch.observer/filing/0001819790-25-000007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819790/000181979025000007/0001819790-25-000007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819790/000181979025000007/tars-20250225.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T04:54:55.883279+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}